Bristol-Myers Squibb Company (NYSE:BMY)
Leerink Partners Rare Disease & Immuno-Oncology Roundtable Conference
September 29, 2016 03:00 PM ET
Executives
Dr. Fouad Namouni - Oncology Development Head
Analysts
Seamus Fernandez - Leerink Swann, LLC
Seamus Fernandez
Hey, good afternoon everybody. I’m Seamus Fernandez, Leerink’s large pharma analyst. We’re very fortunate to have Bristol-Myers here with us today. Perhaps the foremost pioneer in immuno-oncology. And as many of you know, this is our Second Annual Immuno-Oncology Roundtable. With us today is Dr. Fouad Namouni. In late July, Fouad was named Bristol’s Oncology Development Head, responsible for shepherding the Company’s oncology pipeline from early development through commercialization. Prior to his role as Oncology Development Head, Fouad was Head of Medical, leading the worldwide medical organization including development of Yervoy and Opdivo.
